BAY 11-7082 Is a Broad-Spectrum Inhibitor with Anti-Inflammatory Activity against Multiple Targets
Figure 4
Effect of BAY on the activation of the AP-1 pathway. (a to d) HEK293 cells cotransfected with AP-1-Luc construct (1 μg/mL) and β-gal (as a transfection control) were treated with BAY (0 to 20 μM) in the presence or absence of PMA (100 nM) or by cotransfection with AP-1 activation inducers (MyD88, TRIF, and TBK1). Luciferase activity was measured using a luminometer. (e) Translocated or phosphorylated levels of AP-1 family (c-Fos and c-Jun) from the nucleus from RAW264.7 cells treated with BAY (15 μM) in the presence or absence of LPS (1 μg/mL), evaluated by immunoblotting. (f) RAW264.7 cells ( cells/mL) were incubated with BAY (15 μM) in the presence or absence of LPS (1 μg/mL) for indicated times. After preparing total lysates, levels of phospho (p)- or total proteins of JNK, p38, and ERK were identified by immunoprecipitation. (g) Levels of NO determined by the Griess assay and PGE2 by EIA from culture supernatants of RAW264.7 cell treated with U0126 (U0), SB203580 (SB), or SP600125 (SP) in the presence or absence of LPS (1 μg/mL) for 24 h. * and ** compared to the control.
